<DOC>
	<DOCNO>NCT02839161</DOCNO>
	<brief_summary>Double blind , randomize , control , dose-escalation Phase 1 clinical trial hookworm-exposed child age 6 10 year live area Lambaréné , Gabon . Children receive three dos Na-GST-1/Alhydrogel hookworm vaccine co-administered Na-APR-1 ( M74 ) /Alhydrogel hookworm vaccine hepatitis B vaccine co-administered sterile saline . All injection deliver intramuscularly ( deltoid ) approximately Days 0 , 56 , 112 180 .</brief_summary>
	<brief_title>Study Co-administered Na-APR-1 ( M74 ) Na-GST-1 Gabonese Children</brief_title>
	<detailed_description>Double blind , randomize , control , dose-escalation Phase 1 clinical trial hookworm-exposed child age 6 10 year live area Lambaréné , Gabon . Children receive three dos assign vaccine ( ) deliver intramuscularly ( deltoid ) approximately Days 0 , 56 , 112 180 . Safety measure time study vaccination ( Day 0 ) 14 day study vaccination occurrence solicit injection site systemic reactogenicity event . Unsolicited non-serious adverse event ( AEs ) collect time first study vaccination approximately 1 month study vaccination . New-onset chronic medical condition Serious Adverse Events ( SAEs ) collect time first study vaccination approximately 9 month third study vaccination ( final visit ) . Clinical laboratory evaluation safety perform venous blood collect approximately 14 day vaccination . Immunogenicity test include IgG antibody responses vaccine antigen , qualified indirect enzyme-linked immunosorbent assay ( ELISA ) , serum plasma obtain prior study vaccination time point vaccination ( see Appendix A ) ; functional activity vaccine-induced antibody assess vitro enzyme neutralization assay ; induction B cell memory measure antigen-specific memory B cell response . Recruitment enrollment study occur ongoing basis , group recruit vaccinated sequence . 60 subject enrol 3 group 20 . The first 20 subject assemble enrol Group 1 : 1 . Group 1 double-blind IP allocation ( n=20 ) : - 16 subject receive 10 µg Na-APR-1 ( M74 ) plus 5 µg GLA-AF deliver IM injection deltoid muscle , 10 µg Na-GST-1 administer IM alternate arm . - 8 vaccinated accord 0,2,4-month schedule - 8 vaccinated accord 0,2,6-month schedule - 4 subject receive hepatitis B vaccine comparator : - 2 vaccinated accord 0,2,4-month schedule - 2 vaccinated accord 0,2,6-month schedule 2 . Group 2 double-blind IP allocation ( n=20 ) : - 16 subject receive 30 µg Na-APR-1 ( M74 ) plus 5 µg GLA-AF deliver IM injection deltoid muscle , 30µg Na-GST-1 administer IM alternate arm . - 8 vaccinated accord 0,2,4-month schedule - 8 vaccinated accord 0,2,6-month schedule - 4 subject receive hepatitis B vaccine comparator : - 2 vaccinated accord 0,2,4-month schedule - 2 vaccinated accord 0,2,6-month schedule 3 . Group 3 double-blind IP allocation ( n=20 ) : - 16 subject receive 100 µg Na-APR-1 ( M74 ) plus 5 µg GLA-AF deliver IM injection deltoid muscle , 100 µg Na-GST-1 administer IM alternate arm . - 8 vaccinated accord 0,2,4-month schedule - 8 vaccinated accord 0,2,6-month schedule - 4 subject receive hepatitis B vaccine comparator : - 2 vaccinated accord 0,2,4-month schedule - 2 vaccinated accord 0,2,6-month schedule</detailed_description>
	<mesh_term>Hookworm Infections</mesh_term>
	<mesh_term>Ancylostomiasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>1 . Males females 6 10 year , inclusive , longterm resident study area . 2 . Good general health determine mean screening procedure . 3 . Assumed availability duration trial ( 15 month ) . 4 . Willingness parent legal guardian child participate study evidence sign informed consent document combination child assent form . 5 . Negative hookworm screening , find infected hookworm , complete course three dos albendazole . 1 . Inability parent/legal guardian correctly answer question inform consent comprehension questionnaire . 2 . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , diabetes , renal disease history , physical examination , and/or laboratory study . 3 . Known suspected immunodeficiency . 4 . Laboratory evidence liver disease ( alanine aminotransferase [ ALT ] great 1.25times upper reference limit ) . 5 . Laboratory evidence renal disease ( serum creatinine great 1.25times upper reference limit , 1+ protein , trace blood urine dipstick test exception great trace blood detect female menses ) . 6 . Laboratory evidence hematologic disease ( absolute leukocyte count &lt; 4500/mm3 ; absolute leukocyte count &gt; 13.0 x 103/mm3 ; hemoglobin &lt; 9.5 g/dl ; , platelet count &lt; 140,000/mm3 ) . 7 . Other condition opinion investigator could jeopardize safety right child participate trial would render child unable comply protocol . 8 . Participation another investigational vaccine drug trial within 30 day start study duration study . 9 . History severe allergic reaction anaphylaxis . 10 . Severe asthma define need daily use inhaler emergency room/clinic visit hospitalization within 6 month child 's plan first vaccination study . 11 . Positive HCV . 12 . Positive HBsAg . 13 . Positive HIV infection . 14 . Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day start study expect use duration study . 15 . Receipt live vaccine within past 4 week kill vaccine within past 2 week prior entry study . 16 . History surgical splenectomy . 17 . Receipt blood product within 6 month prior entry study . 18 . Previous receipt primary series ( three dos accord 0 , 1 , 6 12 month schedule ) hepatitis B vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hookworm</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Na-GST-1</keyword>
	<keyword>Na-APR-1</keyword>
	<keyword>Necator americanus</keyword>
</DOC>